Mebeverine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
No edit summary
 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{drugbox
{{Drugbox
| IUPAC_name =  
| Watchedfields = changed
| CAS_number =  
| verifiedrevid = 443346749
| ATC_prefix = A03
| IUPAC_name = (''RS'')-4-(ethyl[1-(4-methoxyphenyl)propan-2-yl]amino)butyl 3,4-dimethoxybenzoate
| ATC_suffix = AA04
| image = Mebeverin Wiki Str.png
| ATC_supplemental =  
| width = 300
| PubChem =  
| image2 = Mebeverin Ball n stick.png
| DrugBank =  
| imagename = 1 : 1 mixture (racemate)
| C=25|H=36|O=5|N=1
| drug_name = Mebeverine
| molecular_weight = 430.5595 g/mol
 
| bioavailability =
<!--Clinical data-->
| protein_bound =  
| tradename = Colofac, Duspamen and others
| metabolism =  
| Drugs.com = {{drugs.com|international|mebeverine}}
| elimination_half-life =
| excretion =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_UK = P <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =  
| routes_of_administration = Oral
| routes_of_administration =  
 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 2753-45-9
| ATC_prefix = A03
| ATC_suffix = AA04
| PubChem = 4031
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3891
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7F80CC3NNV
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04868
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 282121
 
<!--Chemical data-->
| C=25 | H=35 | N=1 | O=5
| molecular_weight = 429,6[g/mol]
| smiles = O=C(OCCCCN(C(C)Cc1ccc(OC)cc1)CC)c2cc(OC)c(OC)cc2
| InChI = 1/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3
| InChIKey = VYVKHNNGDFVQGA-UHFFFAOYAR
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VYVKHNNGDFVQGA-UHFFFAOYSA-N
}}
}}


{{SI}}
'''Mebeverine''' is a [[pharmaceutical drug|drug]] whose major therapeutic role is in the treatment of [[irritable bowel syndrome]] (IBS) and the associated abdominal cramping. It works by relaxing the muscles in and around the gut. It is a musculotropic [[antispasmodic]] drug without [[anticholinergic]] side-effects. The drug is also indicated for treatment of gastrointestinal spasm secondary to organic disorder.
 
[[File:Mebeverin Col.png||none|300px]]
 
==Indications==
Spastic functional disturbances of the colon:
* Irritable bowel syndrome in its primary form
* Irritable bowel syndrome associated with organic lesions of the gastrointestinal tract such as; diverticulosis and diverticulitis, regional enteritis, disease of the gall bladder and gall ducts, gastric and duodenal ulcers, dysentery, and aspecific or specific inflammation of the digestive tract.
* Mebeverine should be taken 20 minutes before meals.
 
==Mechanism of action==
Mebeverine is an [[antimuscarinic]]. It belongs to a group of compounds called [[musculotropic antispasmodic]]s. These compounds act directly on the gut muscles at the cellular level to relax them. This relieves painful muscle spasms of the gut, without affecting its normal motility. Mebeverine is used to relieve symptoms of irritable bowel syndrome and related intestinal disorders that are the result of spasms in the intestinal muscles. These include colicky abdominal pain and [[cramps]], [[diarrhoea]] alternating with [[constipation]] and [[flatulence]] (wind).


{{EH}}
Mebeverine is also an inhibitor of calcium-depot replenishment. Therefore, it has dual mode of action which normalizes the small bowel motility.
==Overview==
'''Mebeverine HCI''' is a musculotropic [[antispasmodic]] drug without atropic side-effects whose major therapeutic role is in the treatment of irritable bowel syndrome. It is also indicated for treatment of gastrointestinal spasm secondary to organic disorder. It was first registered in 1965 and manufacture by [[Solvay (company)|Solvay Pharmaceuticals]].


Mebeverine HCI presented in tablets (100mg or 135mg), capsules (200mg slow release), and liquid (10mg/ml).
==Adverse effects==
Side effects may include:<ref name="Colofac Data Sheet">Colofac Data Sheet (PDF) http://www.medsafe.govt.nz/profs/datasheet/c/colofactab.pdf</ref>
* Indigestion or heartburn
* Constipation
* Dizziness
* [[Insomnia]] (difficulty sleeping)
* [[Anorexia (symptom)|anorexia]] (loss of appetite)
* Headache
* Tiredness
* Slow heart beat
* Rash and/or itchy skin


==Mode of Action==
Since 1978, 21 cases of severe adverse reactions to mebeverine were reported in the Netherlands.<ref>{{Cite book|author=in 't Veld BA, van Puyenbroek E, Stricker BH. |title=Hypersensitivity reactions to use of mebeverine| year=1997 |pages=1392–5 |doi=}}
Mebeverine HCI belongs to a group of compounds called musculotropic antispasmodics. These compounds act directly on the gut muscles at the cellular level to relax them. Mebeverine is also an inhibitor of calcium-depot replenishment. Therefore, mebeverine has dual mode of action which normalizes the small bowel motility.
Ned Tijdschr Geneeskd. 1997 July 12;141(28):1392-5.
Hypersensitivity reactions to use of mebeverine  [http://www.ncbi.nlm.nih.gov/pubmed/9380201] pubmed: 9380201</ref>
Most reactions consisted of [[urticaria]] or [[maculopapular rash]], sometimes accompanied by [[fever]], [[polyarthritis]], [[thrombopenia]] or [[angioedema]].
 
Very rarely, people taking this medicine may develop allergic reactions.<ref>Colofac Patient leaflet sheet http://emc.medicines.org.uk/medicine/2531/PIL/Colofac+Tablets+135mg/</ref>
 
==Pregnancy and breastfeeding==
Mebeverine passes into breast milk, but the amount is considered too small to be harmful to a nursing infant.<ref name="Colofac Data Sheet">Colofac Data Sheet (PDF) http://www.medsafe.govt.nz/profs/datasheet/c/colofactab.pdf</ref>
 
==Driving and using machines==
Mebeverine is unlikely to affect the ability to operate machinery or to drive, yet not completely out of the question. <ref>http://www.drugs.com/uk/mebeverine-50mg-5ml-sugar-free-oral-suspension-leaflet.html</ref> <ref>http://www.nhs.uk/medicine-guides/pages/MedicineOverview.aspx?condition=Irritable%20bowel&medicine=mebeverine%20hydrochloride&preparation=Mebeverine%20135mg%20tablets</ref>
 
==History==
It was first registered in 1965.<ref>[http://druginfosys.com/Drug.aspx?DrugCode=438&DrugName=Mebeverine&type=1 Mebeverine page at druginfosys] Page accessed Feb 1, 2015</ref>
 
==Availability==
Mebervine is a [[generic drug]] and is available internationally under many brand names.<ref>[http://www.drugs.com/international/mebeverine.html International page at drugs.com for Mebeverine] Page accessed Feb 1, 2015</ref>
 
==References==
{{Reflist|2}}
 
==External links==
* [http://www.nps.org.au/__data/assets/pdf_file/0019/16543/smccolof.pdf Drug Leaflet]
* [http://colofac.net/ Colofac official site]


{{Drugs for functional gastrointestinal disorders}}
{{Drugs for functional gastrointestinal disorders}}
[[Category: Motility stimulants]]
{{Cholinergics}}
 
{{SIB}}


{{WH}}
[[Category:Motility stimulants]]
{{WikiDoc Sources}}
[[Category:Benzoates]]
[[Category:Phenol ethers]]
[[Category:Amines]]

Latest revision as of 21:41, 6 April 2015

Mebeverine
Clinical data
Trade namesColofac, Duspamen and others
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC25H35NO5
Molar mass429,6[g/mol]
3D model (JSmol)
  (verify)

Mebeverine is a drug whose major therapeutic role is in the treatment of irritable bowel syndrome (IBS) and the associated abdominal cramping. It works by relaxing the muscles in and around the gut. It is a musculotropic antispasmodic drug without anticholinergic side-effects. The drug is also indicated for treatment of gastrointestinal spasm secondary to organic disorder.

Indications

Spastic functional disturbances of the colon:

  • Irritable bowel syndrome in its primary form
  • Irritable bowel syndrome associated with organic lesions of the gastrointestinal tract such as; diverticulosis and diverticulitis, regional enteritis, disease of the gall bladder and gall ducts, gastric and duodenal ulcers, dysentery, and aspecific or specific inflammation of the digestive tract.
  • Mebeverine should be taken 20 minutes before meals.

Mechanism of action

Mebeverine is an antimuscarinic. It belongs to a group of compounds called musculotropic antispasmodics. These compounds act directly on the gut muscles at the cellular level to relax them. This relieves painful muscle spasms of the gut, without affecting its normal motility. Mebeverine is used to relieve symptoms of irritable bowel syndrome and related intestinal disorders that are the result of spasms in the intestinal muscles. These include colicky abdominal pain and cramps, diarrhoea alternating with constipation and flatulence (wind).

Mebeverine is also an inhibitor of calcium-depot replenishment. Therefore, it has dual mode of action which normalizes the small bowel motility.

Adverse effects

Side effects may include:[1]

  • Indigestion or heartburn
  • Constipation
  • Dizziness
  • Insomnia (difficulty sleeping)
  • anorexia (loss of appetite)
  • Headache
  • Tiredness
  • Slow heart beat
  • Rash and/or itchy skin

Since 1978, 21 cases of severe adverse reactions to mebeverine were reported in the Netherlands.[2] Most reactions consisted of urticaria or maculopapular rash, sometimes accompanied by fever, polyarthritis, thrombopenia or angioedema.

Very rarely, people taking this medicine may develop allergic reactions.[3]

Pregnancy and breastfeeding

Mebeverine passes into breast milk, but the amount is considered too small to be harmful to a nursing infant.[1]

Driving and using machines

Mebeverine is unlikely to affect the ability to operate machinery or to drive, yet not completely out of the question. [4] [5]

History

It was first registered in 1965.[6]

Availability

Mebervine is a generic drug and is available internationally under many brand names.[7]

References

  1. ↑ 1.0 1.1 Colofac Data Sheet (PDF) http://www.medsafe.govt.nz/profs/datasheet/c/colofactab.pdf
  2. ↑ in 't Veld BA, van Puyenbroek E, Stricker BH. (1997). Hypersensitivity reactions to use of mebeverine. pp. 1392–5. Ned Tijdschr Geneeskd. 1997 July 12;141(28):1392-5. Hypersensitivity reactions to use of mebeverine [1] pubmed: 9380201
  3. ↑ Colofac Patient leaflet sheet http://emc.medicines.org.uk/medicine/2531/PIL/Colofac+Tablets+135mg/
  4. ↑ http://www.drugs.com/uk/mebeverine-50mg-5ml-sugar-free-oral-suspension-leaflet.html
  5. ↑ http://www.nhs.uk/medicine-guides/pages/MedicineOverview.aspx?condition=Irritable%20bowel&medicine=mebeverine%20hydrochloride&preparation=Mebeverine%20135mg%20tablets
  6. ↑ Mebeverine page at druginfosys Page accessed Feb 1, 2015
  7. ↑ International page at drugs.com for Mebeverine Page accessed Feb 1, 2015

External links

Template:Drugs for functional gastrointestinal disorders

Retrieved from "https://www.wikidoc.org/index.php?title=Mebeverine&oldid=1083748"